The metastatic bladder cancer market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2021-2029. The increasing geriatric population, along with the growing investment in the development of advanced therapies are expected to fuel the progress of this market. The growth of the market can also be attributed to factors such as the increased government spending on intensifying healthcare awareness and rising prevalence of metastatic bladder cancer amongst individuals on a global level. According to National Center for Biotechnology Information, bladder cancer is the tenth most common type of cancer in the world and is estimated to account for 2.1% of all global cancer deaths in 2018.
The market is segmented on the basis of cancer type into urothelial carcinoma, squamous cell carcinoma, adenocarcinoma, and others, out of which, the urothelial carcinoma segment is anticipated to grab the largest share by the end of 2021 on account of being the most common type of metastatic bladder cancer. Moreover, tobacco consumption, which is the most significant risk factor for urothelial carcinoma, is also rising globally, which is also projected to contribute to the growth of the segment during the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT
On the basis of treatment type, the chemotherapy segment in the global metastatic bladder cancer market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that it is the first in-line treatment for metastatic bladder cancer. Moreover, it can also be used along with radiotherapy as a combination therapy as the need arises.
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the increasing awareness about bladder diseases and the need to develop innovative diagnostic and treatment solutions in the region. Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the growing incidence of metastatic bladder cancer, due to the rising elderly population. Along with this, North America also leads in terms of development of innovative treatment solutions, which is also expected to contribute to the market growth in the region. Alternatively, the market in Europe is also anticipated to occupy a significant share in the metastatic bladder cancer market on account of increase in ageing population and a high prevalence of metastatic bladder cancer in the region. According to International Agency for Research on Cancer, in 2020, Europe accounted for 35.6% of the total new bladder cancer cases, and 31.7% of the total bladder cancer deaths globally.
The global metastatic bladder cancer market is further classified on the basis of region as follows:
Our in-depth analysis of the global metastatic bladder cancer market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The increasing geriatric population and growing investment in the development of advanced therapies are the key factors driving market growth.
The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2021-2029.
Expensive metastatic bladder cancer treatment therapies and lack of awareness about the disease in lower economic regions are estimated to hamper market growth.
The market in Asia Pacific region will provide ample growth opportunities owing to the increasing awareness about bladder diseases.
The major players dominating the metastatic bladder cancer market are Pfizer Inc., Sanofi, GlaxoSmithKline PLC, Elli Lilly and Company among others.
The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by cancer type, treatment type and region.
With respect to treatment, the chemotherapy segment is anticipated to hold the largest market share owing to the fact that it is the first in-line treatment for metastatic bladder cancer.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization